DK472988A - Terapeutiske praeparater mod streptokokinfektioner, transformerede vaerter og produkter fremstillet ved genteknologi - Google Patents

Terapeutiske praeparater mod streptokokinfektioner, transformerede vaerter og produkter fremstillet ved genteknologi

Info

Publication number
DK472988A
DK472988A DK472988A DK472988A DK472988A DK 472988 A DK472988 A DK 472988A DK 472988 A DK472988 A DK 472988A DK 472988 A DK472988 A DK 472988A DK 472988 A DK472988 A DK 472988A
Authority
DK
Denmark
Prior art keywords
infections
striptococcin
wars
gent
transformed
Prior art date
Application number
DK472988A
Other languages
Danish (da)
English (en)
Other versions
DK472988D0 (da
Inventor
Edwin H Beachey
Thomas P Poirier
Michael A Kehoe
Original Assignee
Edwin H Beachey
Thomas P Poirier
Michael A Kehoe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edwin H Beachey, Thomas P Poirier, Michael A Kehoe filed Critical Edwin H Beachey
Publication of DK472988D0 publication Critical patent/DK472988D0/da
Publication of DK472988A publication Critical patent/DK472988A/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/879Salmonella
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/885Streptococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK472988A 1987-08-24 1988-08-24 Terapeutiske praeparater mod streptokokinfektioner, transformerede vaerter og produkter fremstillet ved genteknologi DK472988A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/088,626 US5162226A (en) 1987-08-24 1987-08-24 Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products

Publications (2)

Publication Number Publication Date
DK472988D0 DK472988D0 (da) 1988-08-24
DK472988A true DK472988A (da) 1989-02-25

Family

ID=22212456

Family Applications (1)

Application Number Title Priority Date Filing Date
DK472988A DK472988A (da) 1987-08-24 1988-08-24 Terapeutiske praeparater mod streptokokinfektioner, transformerede vaerter og produkter fremstillet ved genteknologi

Country Status (12)

Country Link
US (1) US5162226A (fr)
EP (1) EP0305279B1 (fr)
JP (1) JPH02420A (fr)
AT (1) ATE120487T1 (fr)
AU (1) AU631524B2 (fr)
CA (1) CA1341255C (fr)
DE (1) DE3853454T2 (fr)
DK (1) DK472988A (fr)
FI (1) FI97603C (fr)
HU (1) HU205263B (fr)
NO (1) NO174630C (fr)
PT (1) PT88329B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254874B1 (en) 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6428784B1 (en) * 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US6399097B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corporation Composition for treatment of a bacterial infection of the digestive tract
US20030129147A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6277399B1 (en) * 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US20020136712A1 (en) * 1997-10-31 2002-09-26 Fischetti Vincent Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae
US6752988B1 (en) * 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US6399098B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corp Composition for treating dental caries caused by streptococcus mutans
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6406692B1 (en) 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US7063837B2 (en) * 1999-09-14 2006-06-20 New Horizons Diagnostics Corp Syrup composition containing phage associated lytic enzymes
US7256265B2 (en) * 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
AU2001259205A1 (en) * 2000-04-28 2001-11-12 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US6395504B1 (en) 2000-09-01 2002-05-28 New Horizons Diagnostics Corp. Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants
WO2002102405A1 (fr) * 2000-11-02 2002-12-27 New Horizons Diagnostics Corporation Utilisation d'enzymes lytiques associees a un bacteriophage pour empecher une intoxication alimentaire
US20040213765A1 (en) * 2001-07-13 2004-10-28 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
AU2002365223A1 (en) * 2001-10-26 2003-09-02 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
JP2012508174A (ja) 2008-11-05 2012-04-05 ワイス・エルエルシー β溶血性連鎖球菌(BHS)疾患を予防するための多成分免疫原性組成物
CA2879272A1 (fr) 2012-07-16 2014-01-23 Robert G.K. DONALD Saccharides et leurs utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480779B2 (fr) 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4284537A (en) 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4666847A (en) 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
NZ199866A (en) * 1981-03-09 1984-11-09 Cetus Corp Vaccine for prevention of gastroenteric disease:non-pathogenic strain genetically engineered to comprise genes for adhesin and/or toxoids
US4625252A (en) 1981-09-03 1986-11-25 Basf Aktiengesellschaft Guide system and magnetic tape cassette comprising such a system
US4597967A (en) * 1982-07-27 1986-07-01 The University Of Tennessee Research Corp. Synthetic polypeptide fragments
US4521334A (en) 1982-07-27 1985-06-04 The University Of Tennesse Research Corporation Synthetic polypeptide fragments
US4454121A (en) * 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4919930A (en) * 1983-06-10 1990-04-24 University Of Tennessee Research Corporation Synthetic M proteins-streptococci type 5
US4784948A (en) * 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
IT1217303B (it) * 1984-02-01 1990-03-22 Enterovax Res Pty Ltd Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini
US4666846A (en) 1984-02-17 1987-05-19 Eli Lilly And Company Novel cloning vectors containing selectable genetic markers for use in streptomyces and related organisms

Also Published As

Publication number Publication date
JPH02420A (ja) 1990-01-05
FI97603C (fi) 1997-01-27
HU205263B (en) 1992-04-28
FI883876A0 (fi) 1988-08-22
NO883763L (no) 1989-02-27
NO883763D0 (no) 1988-08-23
DE3853454T2 (de) 1995-11-09
ATE120487T1 (de) 1995-04-15
NO174630C (no) 1994-06-08
US5162226A (en) 1992-11-10
NO174630B (no) 1994-02-28
AU631524B2 (en) 1992-12-03
AU2145188A (en) 1989-03-09
HUT50048A (en) 1989-12-28
PT88329A (pt) 1989-06-30
DK472988D0 (da) 1988-08-24
PT88329B (pt) 1995-07-03
EP0305279A1 (fr) 1989-03-01
DE3853454D1 (de) 1995-05-04
CA1341255C (fr) 2001-06-19
FI97603B (fi) 1996-10-15
EP0305279B1 (fr) 1995-03-29
FI883876A (fi) 1989-02-25

Similar Documents

Publication Publication Date Title
DK472988A (da) Terapeutiske praeparater mod streptokokinfektioner, transformerede vaerter og produkter fremstillet ved genteknologi
NZ512574A (en) Novel streptococcus antigens useful as vaccines
ATE211654T1 (de) Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff
DK0625043T3 (da) Vaccine med rekombinant multivalent M-protein
WO1998008542A3 (fr) Composes et procedes destines au traitement et au diagnostic d'infections mycobacteriennes
IL115047A (en) Immunogenic conjugates comprising pneumococcal polysaccharide and recombinant pneumolysin, vaccines comprising such conjugates and use of such vaccines in the manufacture of medicaments for immunizing against pneumococcal infections
NO980883D0 (no) Forbindelser og fremgangsmåter for immunterapi og diagnose av tuberkulose
AP2000001886A0 (en) Group B streptococcus antigens.
ZA965482B (en) Novel antigen.
WO2003065973A8 (fr) Compositions de vaccins multivalents a base de streptocoques et procedes d'utilisation
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
NZ309713A (en) Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
AU2529095A (en) Vaccine against mycobacterial infections
ATE157258T1 (de) Zubereitungen und behandlungen von pneumonia in tieren
DK125887A (da) Beskyttelse af heste mod streptococcus equi
FI952144A0 (fi) Ei tyypittävissä olevan Haemphilus influenzaen puhdistettu P5 proteiini rokotteena ei tyypittävissä olevalle Haemophilus influenzae -kannalle
ATE107516T1 (de) Pasteurella-impfstoff.
CA2133108A1 (fr) Vaccin a base de toxoide contre pasteurella haemolytica type a-1
AU673344B2 (en) Vaccines based on streptokinase
FR2623399B1 (fr) Procede de fabrication d'antigenes, de vaccins et de serums contre les maladies bacteriennes ou virales et composition mise en oeuvre

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment